Hims & Hers Stock Pops After Q3 Earnings: Here's Why

Hims & Hers Health (HIMS) shares advanced over 6% in extended trading following its third-quarter earnings report, which saw revenue beat analyst estimates at $598.97 million, despite an EPS miss of $0.06 per share. The company also announced active discussions to make Novo Nordisk's Wegovy available on its platform, a significant strategic development. While Hims & Hers reported robust subscriber growth of 21% year-over-year to nearly 2.5 million, its Q4 revenue outlook of $605 million to $625 million fell below analyst expectations.

Analysis

Hims & Hers Health (HIMS) shares experienced a 6.44% surge to $47.28 in extended trading following its third-quarter earnings report, primarily driven by a revenue beat and a significant strategic announcement. The company reported Q3 revenue of $598.97 million, exceeding the Street's estimate of $580.24 million, despite an EPS miss at $0.06 per share against an analyst estimate of $0.09. This strong top-line performance and positive market sentiment (0.7) suggest investor focus on growth drivers.

A key catalyst for the positive market reaction is Hims' active discussions to make Novo Nordisk's (NVO) oral and injectable Wegovy available through its platform. This potential partnership positions Hims to capitalize on the high-demand weight-loss drug market, significantly expanding its service offerings. The company also demonstrated robust organic growth, with subscribers increasing 21% year-over-year to nearly 2.5 million, reinforcing its scaling personalized care model.

While Hims & Hers provided a Q4 revenue outlook of $605 million to $625 million, which fell below the analyst estimate of $631.68 million, the market appears to be prioritizing strategic growth. The fiscal 2025 revenue outlook was narrowed to $2.335 billion to $2.355 billion, closely aligning with the $2.341 billion estimate, indicating a stable longer-term trajectory despite near-term guidance variations.

Key Decisions for Investors

• Investors should closely monitor developments regarding the potential integration of Novo Nordisk's Wegovy onto the Hims & Hers platform, as this strategic move could significantly enhance future revenue and market positioning.
• Consider the company's robust subscriber growth and strategic expansion into new therapeutic areas as key drivers, which appear to be offsetting the Q3 EPS miss and slightly lower Q4 revenue guidance in current market sentiment.
• Evaluate the balance between aggressive market expansion and profitability, paying attention to how future earnings per share performance evolves alongside continued top-line growth.